FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074026912> ?p ?o ?g. }

• W2074026912 abstract "The aim of this study was to evaluate the clinical efficacy of postoperative radiotherapy (PORT), administered using three-dimensional conformal radiotherapy (3D-CRT) and our institutional standard clinical target volume (CTV) delineation, for completely resected stage IIIA(N2) non-small cell lung cancer (NSCLC).From 2005 to 2012, consecutive patients with pT1-3N2 NSCLC who were treated with PORT employing our institutional CTV delineation after complete surgery or who underwent complete resection in our hospital but without PORT were identified. We excluded patients who had received neoadjuvant chemotherapy or radiation therapy (RT). Kaplan-Meier estimates for locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS) and overall survival (OS) were performed. In the OS estimation, patients who received epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) during follow-up were censored at the time of TKI initiation.Data from 70 patients in the PORT group and 287 in the non-PORT group were analysed. All 70 cases received 3D-CRT following our institutional CTV guideline, with a median total dose of 50.4 Gy at 1.8 Gy/fraction. At a median follow-up of 34.3 months for the PORT group and 31.2 months for the non-PORT group, PORT significantly improved local control (5-yr LRFS 91.9% for PORT vs 66.4% for non-PORT, P < 0.001) and OS (5-yr OS 57.5% for PORT vs 35.1% for non-PORT, P = 0.003), whereas no differences in DMFS were noted (P = 0.18). In multivariable analyses, PORT was independently associated with an improved LRFS (HR 0.2, P = 0.001) and OS (HR 0.4, P = 0.001). All patients completed the planned RT dose without interruption of RT due to treatment-related complications.Our data suggested that PORT administered using the 3D-CRT technique following our institutional CTV delineation guideline resulted in a promising outcome with favourable survival for completely resected IIIA(N2) NSCLC, after controlling for subsequent EGFR-TKI confounding in the OS analysis. Prospective trials are needed to further corroborate these results." @default.
• W2074026912 created "2016-06-24" @default.
• W2074026912 creator A5003414240 @default.
• W2074026912 creator A5031866965 @default.
• W2074026912 creator A5038249558 @default.
• W2074026912 creator A5051812511 @default.
• W2074026912 creator A5063127492 @default.
• W2074026912 creator A5064311552 @default.
• W2074026912 creator A5066327832 @default.
• W2074026912 creator A5066884050 @default.
• W2074026912 creator A5088141818 @default.
• W2074026912 date "2015-05-02" @default.
• W2074026912 modified "2023-10-16" @default.
• W2074026912 title "The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume" @default.
• W2074026912 cites W1740332796 @default.
• W2074026912 cites W1907932102 @default.
• W2074026912 cites W1962989085 @default.
• W2074026912 cites W1965535010 @default.
• W2074026912 cites W1967593933 @default.
• W2074026912 cites W1968242472 @default.
• W2074026912 cites W1975585548 @default.
• W2074026912 cites W1985385147 @default.
• W2074026912 cites W1999200326 @default.
• W2074026912 cites W2000623514 @default.
• W2074026912 cites W2004797311 @default.
• W2074026912 cites W2010145979 @default.
• W2074026912 cites W2027592602 @default.
• W2074026912 cites W2032834679 @default.
• W2074026912 cites W2043284501 @default.
• W2074026912 cites W2054930937 @default.
• W2074026912 cites W2061800707 @default.
• W2074026912 cites W2062274192 @default.
• W2074026912 cites W2063315211 @default.
• W2074026912 cites W2063429378 @default.
• W2074026912 cites W2064390193 @default.
• W2074026912 cites W2066968134 @default.
• W2074026912 cites W2086557767 @default.
• W2074026912 cites W2096514839 @default.
• W2074026912 cites W2113765668 @default.
• W2074026912 cites W2120225336 @default.
• W2074026912 cites W2124618551 @default.
• W2074026912 cites W2158499570 @default.
• W2074026912 cites W4255952623 @default.
• W2074026912 cites W4299849031 @default.
• W2074026912 doi "https://doi.org/10.1186/s12885-015-1326-6" @default.
• W2074026912 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4424589" @default.
• W2074026912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25934006" @default.
• W2074026912 hasPublicationYear "2015" @default.
• W2074026912 type Work @default.
• W2074026912 sameAs 2074026912 @default.
• W2074026912 citedByCount "25" @default.
• W2074026912 countsByYear W20740269122016 @default.
• W2074026912 countsByYear W20740269122017 @default.
• W2074026912 countsByYear W20740269122018 @default.
• W2074026912 countsByYear W20740269122019 @default.
• W2074026912 countsByYear W20740269122020 @default.
• W2074026912 countsByYear W20740269122021 @default.
• W2074026912 countsByYear W20740269122022 @default.
• W2074026912 countsByYear W20740269122023 @default.
• W2074026912 crossrefType "journal-article" @default.
• W2074026912 hasAuthorship W2074026912A5003414240 @default.
• W2074026912 hasAuthorship W2074026912A5031866965 @default.
• W2074026912 hasAuthorship W2074026912A5038249558 @default.
• W2074026912 hasAuthorship W2074026912A5051812511 @default.
• W2074026912 hasAuthorship W2074026912A5063127492 @default.
• W2074026912 hasAuthorship W2074026912A5064311552 @default.
• W2074026912 hasAuthorship W2074026912A5066327832 @default.
• W2074026912 hasAuthorship W2074026912A5066884050 @default.
• W2074026912 hasAuthorship W2074026912A5088141818 @default.
• W2074026912 hasBestOaLocation W20740269121 @default.
• W2074026912 hasConcept C119599485 @default.
• W2074026912 hasConcept C126322002 @default.
• W2074026912 hasConcept C127413603 @default.
• W2074026912 hasConcept C141071460 @default.
• W2074026912 hasConcept C143998085 @default.
• W2074026912 hasConcept C146357865 @default.
• W2074026912 hasConcept C151730666 @default.
• W2074026912 hasConcept C2776256026 @default.
• W2074026912 hasConcept C2780140570 @default.
• W2074026912 hasConcept C32802771 @default.
• W2074026912 hasConcept C509974204 @default.
• W2074026912 hasConcept C71924100 @default.
• W2074026912 hasConcept C86803240 @default.
• W2074026912 hasConceptScore W2074026912C119599485 @default.
• W2074026912 hasConceptScore W2074026912C126322002 @default.
• W2074026912 hasConceptScore W2074026912C127413603 @default.
• W2074026912 hasConceptScore W2074026912C141071460 @default.
• W2074026912 hasConceptScore W2074026912C143998085 @default.
• W2074026912 hasConceptScore W2074026912C146357865 @default.
• W2074026912 hasConceptScore W2074026912C151730666 @default.
• W2074026912 hasConceptScore W2074026912C2776256026 @default.
• W2074026912 hasConceptScore W2074026912C2780140570 @default.
• W2074026912 hasConceptScore W2074026912C32802771 @default.
• W2074026912 hasConceptScore W2074026912C509974204 @default.
• W2074026912 hasConceptScore W2074026912C71924100 @default.
• W2074026912 hasConceptScore W2074026912C86803240 @default.
• W2074026912 hasIssue "1" @default.
• W2074026912 hasLocation W20740269121 @default.
• W2074026912 hasLocation W20740269122 @default.
• W2074026912 hasLocation W20740269123 @default.

• next